| Literature DB >> 31842504 |
Marco Paolini1, David Lester2, Michael Hawkins3, Ameth Hawkins-Villarreal4,5, Denise Erbuto6, Andrea Fiorillo7, Maurizio Pompili6.
Abstract
Background and objectives: In recent years, a growing body of research has focused on identifying possible biological markers for suicidal behavior, including infective and immunological markers. In this paper, our aim was to review available evidence concerning the association between cytomegalovirus (CMV) infection and suicide. Materials andEntities:
Keywords: CMV; antibodies; biomarker; cytomegalovirus; review; suicide
Mesh:
Substances:
Year: 2019 PMID: 31842504 PMCID: PMC6956346 DOI: 10.3390/medicina55120782
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Figure 1PRISMA flow diagram.
Studies in Healthy Subjects.
| Study (Year) | Type of Study | Study Population | Case Population | Control Population | Analysis Method | Outcome |
|---|---|---|---|---|---|---|
| Burgdorf et al. [ | Case control study | Data from 81,912 individuals from the Danish blood donor study. Total sample: 11,546 cases and controls | Blood donors who died by suicide or engaged in suicide attempts ( | Blood donors who did not die by suicide or engage in suicide attempts ( | IgG anti cytomegalovirus (CMV). Solid phase ELISA | Seropositivity: 439/655 (67%) vs. 3886/6503 (59.7%), OR 1.31, 95% CI 1.10–1.56 |
| Zhang et al. [ | Cross-sectional observational study | Suicide attempters from inpatients at Lund University Hospital, Sweden. | Patients admitted for suicide attempt ( | People randomly selected from the municipal population with no psychiatric condition or previous suicide attempt ( | IgG anti CMV, CMV titer. ELISA | Seropositivity: 33/53 (62.2%) vs. 16/29 (55.1%). |
| Controls from municipal population of Lund, Sweden. Total sample: 84 cases and controls | CMV IgG titer: 99.5 (±86.9) vs. 91.3 (±92.0) |
Studies in Psychiatric Patient.
| Study (Year) | Type of Study | Study Population | Case Population | Control Population | Analysis Method | Outcome |
|---|---|---|---|---|---|---|
| Dickerson et al. 2018 [ | Prospective study with 16y FU | Individuals with previous diagnosis of schizophrenia spectrum disorder, bipolar disorder or major depressive disorder. Total sample: 1292 individuals | Individuals with serious mental illness who died by suicide ( | Individuals with serious mental illness who did not die by suicide ( | IgG anti-CMV titer. Solid phase ELISA. Antibody levels expressed as a ratio between the test sample divided by that of a standard control sample. | CMV IgG titer: 3.35 (±3.07) vs. 1.59 (±1.90). Association found between increasing levels of antibodies and Hazard Ratios. |
| Dickerson et al. 2017 [ | Cross-sectional study | Individuals with previous diagnosis of schizophrenia spectrum disorder, bipolar disorder or major depressive disorder. Total sample: 162 patients | Individuals with serious mental illness with previous suicide attempts ( | Individuals with serious mental illness without a previous suicide attempt ( | Anti-CMV IgG and IgM titer. Solid phase ELISA. | Association between suicide attempts and IgM anti CMV measured as a continuous variable (coefficient 0.151). Increased odds of suicide for levels of IgM anti CMV ≥ 75th and 90th percentiles (OR 3.02 and 6.31 respectively). No association with IgG. |
| Okusaga et al. 2011 [ | Cross-sectional study | Patients diagnosed with schizophrenia through SCID, recruited in the Munich area of Germany. Total sample: 950 patients | 351 individuals with schizophrenia with previous suicide attempts. | 599 individuals with schizophrenia with no previous suicide attempt. | IgG anti-CMV. Solid phase ELISA. | Seropositivity for CMV not associated with a history of suicide attempt. No further data provided. |